First‐In‐Human, First‐In‐Class, Phase I Trial of the Fucosylation Inhibitor SGN‐2FF in Patients with Advanced Solid Tumors

Lessons Learned Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy for treating a broad range of cancers. In this first‐in‐human, first‐in‐class, phase I study in advanced solid tumors, SGN‐2FF demonstrated...

Ausführliche Beschreibung